SPRB Stock Analysis: Buy, Sell, or Hold?
SPRB - Spruce Biosciences, Inc. Common Stock
$53.05
1.47 (2.85%)
▲
5d:
+0.25%
30d:
+23.14%
90d:
+3.87%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SPRB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SPRB shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$161.64
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$100.36
47.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $53.05, which is considered extended relative to its 30-day fair value range of $42.91 to $50.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.5) compared to its historical average (14.1). Remarkably, the market is currently pricing in an annual earnings decline of 22.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is in a strong downtrend. Immediate support is located at $45.01, while resistance sits at $54.93.
Market Sentiment: SPRB scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $147.88 (+179.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRB is in a strong downtrend. Immediate support is located at $45.01, while resistance sits at $54.93.
Market Sentiment: SPRB scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $147.88 (+179.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$42.91 -
$50.56
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 179.4% below Wall St target ($147.88)
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$42.91 -
$50.56
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$45.01
Resistance Level
$54.93
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.47
Wall Street Target
$147.88
(+179.4%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-22.9% cheaper
PE vs Historical
6.5 vs 14.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.9%
(market-implied from PE analysis)
1-Year Target
$47.63
(-10%)
2-Year Target
$42.87
(-19%)
3-Year Target
$38.58
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→14)
$84.10
(+59%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.5 to 14.1
Stabilization Target:
$115.36
(+118.0%)
PE Expansion Potential:
+118.0%
Share & Embed Analysis
Last updated: August 24, 2026 10:24 AM ET
Data refreshes hourly during market hours. Next update: 11:24 AM
Data refreshes hourly during market hours. Next update: 11:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$121 | 41 HOLD |
